Budesonide, Glycopyrrolate, and Formoterol Fumarate

Budesonide, glycopyrrolate, and formoterol fumarate is a fixed-dose triple combination delivered from a single pressurized inhaler, marketed under the brand name Breztri Aerosphere. It combines an inhaled corticosteroid (budesonide) with two long-acting bronchodilators to treat chronic obstructive pulmonary disease, and more recently, uncontrolled asthma. The combination works because each drug targets a different piece of the disease: airway inflammation, cholinergic-driven bronchoconstriction, and beta-2 receptor-mediated smooth muscle relaxation. What makes it clinically significant is that large trials have shown it reduces flare-ups, improves breathing capacity, and in one pivotal study, cut the risk of death roughly in half compared with dual bronchodilator therapy alone.

What Each Component Does

Budesonide is the anti-inflammatory anchor. As a corticosteroid, it damps down the chronic inflammation in the airways that drives much of the tissue damage and mucus overproduction in COPD. It does not open the airways on its own, but by reducing swelling and immune-cell activity, it creates conditions where the two bronchodilators can work more effectively.

Glycopyrrolate (also called glycopyrronium) is a long-acting muscarinic antagonist. It blocks the receptors that cause airway smooth muscle to contract when stimulated by the neurotransmitter acetylcholine. Research on human airway tissue has confirmed that glycopyrrolate binds these receptors with high affinity in the nanomolar range, producing sustained relaxation of the airway walls.¹

Formoterol fumarate is a long-acting beta-2 agonist that stands out for how quickly it kicks in. Unlike some long-acting bronchodilators that take 30 minutes or more to produce noticeable relief, formoterol begins opening airways within about five minutes while still lasting over 12 hours.² That rapid onset combined with a long duration of action is what distinguishes it from other drugs in its class.³ Pairing glycopyrrolate with formoterol means you get two bronchodilators working through completely different mechanisms, so the airway-opening effect is greater than either alone.

How Well It Works for COPD

The key evidence comes from two large randomized trials, KRONOS and ETHOS. In KRONOS, a 24-week study, patients on the triple combination had significantly better lung function than those on two-drug regimens. Compared with budesonide-formoterol alone (no glycopyrrolate), the triple combination improved the four-hour average lung capacity measure by about 104 mL. Compared with an established dry-powder budesonide-formoterol inhaler, the improvement was about 91 mL.⁴ Those numbers may sound modest in absolute terms, but for people with COPD, even small improvements in airflow translate into noticeably easier breathing during daily activities.

ETHOS was the larger and longer follow-up, enrolling more than 8,500 patients over 52 weeks. The annual rate of moderate or severe flare-ups with the higher-dose triple therapy was about 1.08 per patient per year, compared with 1.42 for the dual-bronchodilator arm without budesonide. That amounts to roughly a 24% reduction in exacerbations. Even compared with budesonide-formoterol (which already contains a steroid), the triple combination reduced flare-ups by about 13%.⁵ For a disease where every exacerbation accelerates lung function decline and can land someone in the hospital, that margin matters.

The Mortality Signal

Perhaps the most striking finding from ETHOS was the survival benefit. In the final dataset, which captured vital status for nearly all participants, the higher-dose triple therapy cut the risk of dying from any cause by about half compared with the dual-bronchodilator combination (glycopyrrolate-formoterol). The comparison with budesonide-formoterol did not reach statistical significance, suggesting the survival advantage is driven by adding the corticosteroid on top of two bronchodilators rather than by adding a second bronchodilator to a steroid-containing regimen.⁶

A separate indirect comparison matched the ETHOS data against the IMPACT trial, which tested a competing triple inhaler (fluticasone furoate/umeclidinium/vilanterol). After statistical adjustment, all-cause mortality over 52 weeks was about 39% lower with budesonide/glycopyrrolate/formoterol than with the competitor triple therapy.⁷ That finding has to be interpreted cautiously because it is a cross-trial comparison rather than a head-to-head randomized study. But a real-world cohort study also found that patients starting the single-inhaler triple combination had an 18% lower risk of all-cause death compared with those on multiple-inhaler triple therapy regimens.⁸

Blood Eosinophils and Who Benefits Most

Not everyone with COPD gets the same payoff from adding a corticosteroid. The biggest predictor of benefit is the eosinophil count in a routine blood test. Eosinophils are white blood cells involved in a particular type of airway inflammation, and when their levels are higher, inhaled steroids have more inflammation to suppress.

Post-hoc analyses from ETHOS showed that the triple combination reduced exacerbations versus dual bronchodilators across a range of eosinophil levels, but the advantage widened as eosinophil counts climbed. Patients with counts of 300 or more per microliter saw the largest reductions in flare-ups, the greatest improvements in symptom scores, and the most benefit on quality-of-life measures. In patients with counts below 100, the exacerbation benefit was still present but the improvements in symptoms and quality of life were harder to detect.⁹

A parallel analysis from the KRONOS trial found a similar gradient. Among patients with eosinophil counts between 100 and 300, the triple combination reduced moderate or severe exacerbation rates by roughly 47% to 56% compared with the dual-bronchodilator arm, depending on disease severity and exacerbation history.¹⁰ This eosinophil-guided approach is now embedded in international COPD guidelines, which recommend that triple therapy including an inhaled corticosteroid be reserved for patients who remain symptomatic or keep having flare-ups despite dual bronchodilator therapy, with biomarkers helping guide the decision.¹¹

Safety Profile and Common Side Effects

The main safety concern with any inhaler that contains a corticosteroid is the local and systemic effects of that steroid. In clinical trials, hoarseness (dysphonia) and oral thrush (candidiasis) were more common with the triple combination than with dual bronchodilators alone.¹² Both are manageable: rinsing the mouth after each use reduces thrush, and hoarseness typically resolves if the inhaler technique is corrected or the dose adjusted.

Pneumonia is the side effect that draws the most clinical attention with inhaled corticosteroids in COPD. Interestingly, in one 52-week safety study, the confirmed pneumonia rate was actually lowest in the dual-bronchodilator group at about 3.4%, while the triple therapy group came in at 2.1%.¹³ That finding has not been entirely consistent across all analyses, and experts generally still counsel that adding any inhaled steroid carries some degree of pneumonia risk, particularly in patients who are older or have more severe disease. A systematic review comparing the triple combination with glycopyrrolate-formoterol alone found overall adverse event profiles were similar, with the most common events being nasopharyngitis and upper respiratory infections in both groups.¹⁴ Bone density and eye-related effects such as cataracts and glaucoma were also tracked and did not differ meaningfully between groups over 52 weeks.

Why a Single Inhaler Matters for Adherence

Before single-inhaler triple therapy existed, patients who needed all three drug classes had to juggle two or even three separate devices, each with its own technique and dosing schedule. That complexity erodes adherence. A retrospective study of COPD patients in Spain found that after 12 months, about 75% of single-inhaler users were still adherent compared with 70% on multiple inhalers. More strikingly, persistence (continuing therapy at all) was about 64% versus 52%, and moderate exacerbation rates were lower in the single-inhaler group.¹⁵

The same pattern appeared in a Japanese cohort, where single-inhaler users had significantly better adherence and persistence at 6, 12, and 18 months.¹⁶ The practical lesson is straightforward: fewer devices means fewer opportunities to skip a dose or use one incorrectly. For a disease where missing doses can trigger a worsening spiral, that convenience has measurable clinical consequences.

How It Compares With the Other Single-Inhaler Triple Therapy

The main market competitor is fluticasone furoate/umeclidinium/vilanterol, sold as Trelegy Ellipta. It is a dry-powder inhaler rather than a pressurized metered-dose inhaler, which means the devices feel different and require different inhalation techniques. The clinical question of whether one is better than the other does not have a clean answer yet.

A large real-world cohort study in the BMJ found that patients starting budesonide/glycopyrrolate/formoterol had a 9% higher rate of first moderate or severe exacerbation compared with those starting the competitor, with no meaningful difference in pneumonia hospitalization rates.¹⁷ That slight exacerbation disadvantage is worth knowing about, though it should be weighed against the earlier-mentioned indirect comparison that suggested a mortality advantage going in the other direction. These are different study designs measuring different outcomes, and it is entirely possible for one product to be slightly worse at preventing mild flare-ups while being associated with better survival if, for example, its corticosteroid component has a different safety profile at the lung level.

An analysis of adverse-event reports across three international pharmacovigilance databases highlighted different signal profiles for each product. The budesonide-based triple had a relatively small number of total reports but flagged device-related issues like delivery-system problems. The competitor, with far more reports overall, showed signals related to packaging confusion and foreign-body sensations.¹⁸ Neither product emerged as clearly safer overall; the differences were more about the type of device than the drugs themselves.

Expanding Into Asthma

Although the combination was originally developed for COPD, two large phase 3 trials called KALOS and LOGOS recently tested it in adults with uncontrolled asthma who were already on medium- or high-dose inhaled corticosteroid plus a long-acting beta agonist. Both trials met their primary endpoints. Patients on the triple combination gained about 76 mL more in trough lung capacity compared with budesonide-formoterol, and severe exacerbation rates dropped by roughly 14% to 18% depending on the comparison arm.¹⁹

What makes this interesting is that the benefit appeared regardless of whether patients had recently experienced an exacerbation. Current guidelines for asthma typically require a recent flare-up before escalating therapy. These data suggest there may be a broader population of poorly controlled asthma patients who could benefit from adding a long-acting muscarinic antagonist to their existing steroid-and-bronchodilator regimen, without waiting for things to get worse first.

When to Consider Stepping Back Down

Triple therapy is not necessarily a permanent commitment. For patients whose condition stabilizes, especially if their eosinophil counts are low and they have not had exacerbations for an extended period, withdrawing the corticosteroid and stepping down to dual bronchodilator therapy is a reasonable conversation. A systematic review and meta-analysis of de-escalation studies found that patients with eosinophil counts of 300 or higher per microliter had a significant increase in exacerbation risk when the steroid was removed, with about a 35% higher hazard. Importantly, the withdrawal did not affect mortality or pneumonia rates overall.²⁰

A large real-world study echoed that finding: patients with two or more exacerbations in the prior year and those with very severe airflow obstruction saw a trend toward more severe flare-ups after stepping down, while other patient groups could be safely transitioned off the steroid component.²¹ The upshot is that the eosinophil count remains the most useful guide: the same biomarker that predicts who benefits from adding a steroid also predicts who will suffer when it is taken away.

Cost-Effectiveness

Triple therapy costs more upfront than dual combinations, so the economic question is whether the exacerbation reductions and quality-of-life gains justify the price. Modeling studies from Spain estimated that over a lifetime horizon, the triple combination produced fewer exacerbations, more life-years, and more quality-adjusted life-years than either dual bronchodilator or steroid-bronchodilator combinations. The incremental cost per quality-adjusted life-year gained was well below conventional willingness-to-pay thresholds in that country.²² A parallel economic evaluation in China reached similar conclusions, with the cost per quality-adjusted life-year consistently falling below the national threshold.²³ Much of the savings come from fewer hospitalizations for exacerbations, which are the single largest cost driver in advanced COPD.

The Inhaler Technology Itself

Delivering three drugs from one canister is harder than it sounds. Each compound has different physical properties, and getting them all to deposit uniformly in the lungs requires careful engineering. The Aerosphere platform uses a co-suspension delivery technology, where the drug crystals are attached to porous phospholipid particles that keep the formulation stable and ensure a consistent fine-particle fraction with each puff.²⁴ A gamma-scintigraphy study, where researchers tagged the drugs with a radioactive tracer and imaged where they landed in the lungs, confirmed that the triple combination distributed throughout both the central and peripheral airways in a consistent pattern.²⁵

Because it is a pressurized metered-dose inhaler, it does not depend on how hard you breathe in the way a dry-powder device does. That can be an advantage for patients with very severe airflow limitation who struggle to generate the fast inhalation flow needed for powder inhalers.

The Propellant Switch and Environmental Impact

One often overlooked aspect of metered-dose inhalers is the propellant that pushes the drug out of the canister. The current version uses HFA-134a, a hydrofluoroalkane that is far better than the ozone-depleting chlorofluorocarbons it replaced decades ago but still has a meaningful global warming potential. The manufacturer is now transitioning to a next-generation propellant called HFO-1234ze(E), which has near-zero global warming potential.²⁶ For a product used twice daily by millions of people worldwide, that switch carries genuine environmental significance. Early pharmaceutical assessments indicate the reformulated product maintains the same drug delivery characteristics, which is critical because any change in propellant can alter particle size and lung deposition.